Novel pharmacological agents in clinical development for solid tumours

G. K. Dy, P. Haluska, A. A. Adjei

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.

Original languageEnglish (US)
Pages (from-to)2059-2088
Number of pages30
JournalExpert Opinion on Investigational Drugs
Issue number12
StatePublished - Jan 1 2001


  • Angiogenesis
  • Antisense oligonucleotide
  • Cyclin-dependent kinase
  • Extracellular matrix
  • Farnesyltransferase inhibitors
  • Heat shock protein
  • Monoclonal antibodies
  • Proteasome
  • Protein kinase C inhibitors
  • Ras
  • Receptor tyrosine kinase inhibitors
  • Signal transduction
  • Ubiquitin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Novel pharmacological agents in clinical development for solid tumours'. Together they form a unique fingerprint.

Cite this